Syros Pharmaceuticals Inc (SYRS.OQ)
Get access to over 18 million research reports from over 1,700 sources.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
- private equity
- third-party document and information retrieval
- and much, much more…
- BRIEF-Syros Pharma Q3 loss per share $0.53
- BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425
- BRIEF-Syros Pharmaceuticals says board appointed CEO Nancy Simonian as company's principal financial officer - SEC Filing
- BRIEF-Syros pharmaceuticals - expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017
- BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML